Status:
WITHDRAWN
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Lead Sponsor:
Morphotek
Conditions:
Resectable, Non-functioning Pituitary Adenoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.
Detailed Description
Non-functioning pituitary adenomas are the most frequent type of pituitary tumors, defined by the lack of hormonal overproduction from the tumor. Non-functioning macroadenomas are \> 1 cm in size that...
Eligibility Criteria
Inclusion
- Males and females \>18 years old
- Diagnosis of non-functional pituitary adenoma
- Able and willing to undergo surgical resection of the pituitary tumor
- Significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form
Exclusion
- Presence of clinically significant pituitary apoplexy
- Presence of hormone-secreting adenomas
- Presence of compressive optic neuropathy due to pituitary tumor
- No prior surgical, medical, or radiation therapy in the last 6 months
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01203618
Start Date
February 1 2011
End Date
August 1 2013
Last Update
November 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University
Atlanta, Georgia, United States, 30322